Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methotrexate for multiple sclerosis.

O Gray, G V McDonnell, R B Forbes

    The Cochrane Database of Systematic Reviews
    |April 24, 2004
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Effects of Mind-body Movement Interventions for Managing Symptoms in People with Multiple Sclerosis: An Overview of Reviews.

    Current neurology and neuroscience reports·2026
    Same author

    Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom.

    Journal of medical economics·2023
    Same author

    A rare characteristic neuroimaging pattern in hyperammonaemia.

    The Ulster medical journal·2017
    Same author

    Acute neuromuscular respiratory failure: a population-based study of aetiology and outcome in Northern Ireland.

    Postgraduate medical journal·2014
    Same author

    Paraneoplastic sensorimotor neuropathy associated with regression of small cell lung carcinoma.

    BMJ case reports·2012
    Same author

    Transient cardiomyopathy as the presenting feature of acute disseminated encephalomyelitis.

    Multiple sclerosis (Houndmills, Basingstoke, England)·2009
    Same journal

    Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

    The Cochrane database of systematic reviews·2026
    Same journal

    Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

    The Cochrane database of systematic reviews·2026
    Same journal

    Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

    The Cochrane database of systematic reviews·2026
    Same journal

    Non-pharmacological interventions for anxiety and depression in Parkinson's disease.

    The Cochrane database of systematic reviews·2026
    Same journal

    Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

    The Cochrane database of systematic reviews·2026
    Same journal

    Preconception and first-trimester metformin for improving pregnancy outcomes in women with polycystic ovary syndrome.

    The Cochrane database of systematic reviews·2026
    See all related articles

    Methotrexate may offer a slight benefit in reducing relapses and disease progression for multiple sclerosis (MS). However, current evidence is limited, necessitating further clinical trials to confirm efficacy and safety in MS patients.

    Area of Science:

    • Neurology
    • Immunology

    Background:

    • Methotrexate is an immunosuppressant with theoretical benefits for multiple sclerosis (MS).
    • Clinical trials have investigated methotrexate's efficacy in managing MS progression and relapses.

    Purpose of the Study:

    • To evaluate the efficacy and safety of methotrexate for individuals with multiple sclerosis.
    • To identify and summarize existing evidence on methotrexate's impact on MS relapse rates and disease progression.

    Main Methods:

    • Systematic review of randomized controlled trials (RCTs) of methotrexate for MS.
    • Searched multiple databases including Cochrane, MEDLINE, and EMBASE up to June 2001.
    • Included one trial of 60 participants with chronic progressive MS; contacted authors for missing data.

    Related Experiment Videos

    Main Results:

    • The included trial showed a non-significant trend towards reduced EDSS progression and relapses with methotrexate.
    • No significant difference in time to first relapse was observed.
    • Minor side effects were common in both methotrexate and placebo groups, with no major adverse events reported.

    Conclusions:

    • A single trial suggests a non-significant trend favoring methotrexate for progressive MS.
    • Further rigorous trials are required to establish the efficacy of methotrexate in multiple sclerosis.
    • Existing evidence is insufficient to draw definitive conclusions on methotrexate's role in MS management.